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OBJECTIVE—Insulin has mitogenic effects, although hypergly-
cemia may be a risk factor for cancer in type 2 diabetes. It
remains uncertain whether use of insulin increases cancer risk
because of its effect on cell growth and proliferation or decreases
cancer risk because of its glucose-lowering effect.
RESEARCH DESIGN AND METHODS—A 1:2-matched new
insulin user cohort on age (3 years), smoking status, and
likelihood of initiating insulin therapy (0.05) was selected from
a cohort of 4,623 Chinese patients with type 2 diabetes, free of
cancer, and naive to insulin at enrollment. Stratiﬁed Cox regres-
sion analysis on the matched pairs was used to obtain hazard
ratios (HRs) of insulin therapy and A1C for cancer risk. A
structured adjustment scheme was used to adjust for covariates.
RESULTS—Of 973 new insulin users, 971 had matched nonusers
(n  1935). The cancer incidence in insulin nonusers was much
higher than that in insulin users (49.2 vs. 10.2, per 1,000 person-
years, P  0.0001). After further adjustment for all other covari-
ates with a P value less than 0.3 and nonlinear associations with
cancer, A1C was associated with an increased cancer risk (HR
per percentage 1.26, 95% CI 1.03–1.55), whereas use of insulin
was associated with a decreased cancer risk (HR of insulin users
vs. nonusers: 0.17, 0.09–0.32). Consistent results were found in
analyses including all 973 insulin users and 3,650 nonusers.
CONCLUSIONS—In Chinese patients with type 2 diabetes, hyper-
glycemia predicts cancer, whereas insulin usage was associated
with a reduced cancer risk. Diabetes 59:1254–1260, 2010
I
nsulin has mitogenic effects and is a stimulator and
regulator of growth and proliferation of a variety of
somatic cells (1). It is suggested that insulin resis-
tance and hyperinsulinemia may be important risk
factors for cancer (2–4). Recently, heated debates fol-
lowed the publication of a series of observational studies
that examined associations between use of insulin, in
particular insulin glargine, and cancer (5–8), accompanied
by an editorial (9). On the other hand, a randomized
controlled trial of 1,017 patients followed for more than 4
years (1,524 days in the insulin glargine group and 1,522
days in the neutral protamine Hagedorn insulin group)
reported that the insulin glargine group had numerically
lower risks of all neoplasms (relative risk: 0.9, 95% CI
0.64–1.26) and all malignant neoplasms (relative risk 0.63,
95% CI 0.36–1.09) than the neutral protamine Hagedorn
insulin group (10). Garg et al. (11) reviewed these studies
and concluded that none of these observational studies
found an overall increased cancer risk with insulin
glargine.
Two studies have reported that hyperglycemia is asso-
ciated with increased risks of colorectal cancer or non–
speciﬁc site cancer (12,13). Our group reported that
abnormal lipids that may stem from hyperglycemia (14)
were predictive of cancer in type 2 diabetes (15,16). It has
been established that there is cross talk between lipid
biosynthesis and renin-angiotensin system (RAS) in ath-
erosclerosis (17), which may be mediated by increased
oxidative stress (18). Our group further reported that the
cross talk may be associated with increased risk of cancer
in type 2 diabetes via increased activity of hydroxymeth-
ylglutaryl-CoA reductase (HGMCR) and insulin-like
growth factor-I (IGF-I) pathways (19). It is also proven that
hyperglycemia has a potent but reversible effect on LDL
oxidation (20). Thus, if tight control of hyperglycemia can
improve lipid metabolism, attenuate RAS activity, and
reduce oxidative stress, it is plausible that use of insulin
may reduce risk of cancer in type 2 diabetes by lowering
blood glucose.
Based on this premise, we argue that use of insulin in
type 2 diabetes would have dual effects: increasing cancer
risk because of its effect on cell growth and proliferation
and decreasing cancer risk because of improved internal
milieu. To test the overall effects of use of insulin on
cancer in Chinese patients with type 2 diabetes, we
explored associations among insulin use, hyperglycemia,
and incident cancer using the Hong Kong Diabetes
Registry.
RESEARCH DESIGN AND METHODS
Patients. The Hong Kong Diabetes Registry was established in 1995, at the
Prince of Wales Hospital, the teaching hospital of the Chinese University of
Hong Kong. The hospital serves a population of more than 1.2 million. The
referral sources of the cohort included general practitioners, community
clinics, other specialty clinics, the Prince of Wales Hospital itself, and other
hospitals. Enrolled patients with hospital admissions within 6–8 weeks prior
to assessment accounted for less than 10% of all referrals. The methods for
recruitment and clinical measurements have been described in the previous
analysis (15). A 4-h assessment of complications and risk factors was
performed on an outpatient basis, modiﬁed from the European DiabCare
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he/she was considered to have entered this study cohort and would be
followed until the time of death. Ethics approval was obtained from the
Chinese University of Hong Kong Clinical Research Ethics Committee. The
Declaration of Helsinki was adhered to and informed consent was obtained
from all the patients, at the time of assessment, for data analysis and research
purposes.
Hong Kong has a highly subsidized health care system. The Hospital
Authority is the governing body of all publicly funded hospitals and outpatient
clinics. The public hospitals provide 95% of the total hospital bed–days and
80% of the outpatient visits, especially for patients with chronic and serious
diseases, because of the noncompulsory nature of medical insurance in Hong
Kong (22). In this analysis, the clinical end points, including discharge
diagnoses and mortality from enrollment to 30 July 2005, were recorded or
otherwise censored on 30 July 2005. Details of all medical admissions of the
cohort by that date were retrieved from the Hong Kong Hospital Authority
Central Computer System, which recorded admissions to all public hospitals
(23). Mortality data from the Hong Kong Death Registry were also retrieved
and cross-checked with hospital discharge status (22). In Hong Kong, all
medications are dispensed on site in both inpatient and outpatient settings.
Drug use data were extracted from the Hospital Authority computer system
that recorded drug dispensary data in all public hospitals including the start
dates and end dates for each of the major drugs. The databases were matched
by a unique identiﬁcation number, the Hong Kong Identity Card number,
which is compulsory for all residents in Hong Kong.
Drug prescription data have been computerized since 1 December 1996.
From that date to 8 January 2005, 7,387 diabetic patients were enrolled in the
registry. We sequentially excluded 328 patients with type 1 diabetes or missing
data on type of diabetes, 45 with non-Chinese or unknown nationality, 175
with a known history of cancer or who were receiving cancer treatment at
enrollment, 736 with missing values on any variables used in the analysis (see
Table 2 for the list of variables), and 1,480 who had used insulin before
enrollment. In the remaining 4,623 patients, we created a new-user subcohort
(n  2,906) followed by sensitivity analysis in the original cohort (Fig. 1).
Study design. Prevalent users can contribute to two types of bias: 1)
insufﬁcient ascertainment of clinically silent events that may occur early in
therapy and 2) the inability to control for disease risk factors that may have
been altered by the study drugs under research (24). Thus, prevalent user bias
is considered to be one of the major contributing factors that results in the
discrepancies between observational studies and clinical trials (24). New-user
designs are developed to eliminate both biases by restricting the analysis to
people under observation at the start of the current course of treatment (24).
In this study, we used a new-user cohort study design with one insulin user
matched to two nonuser subjects on 1) age (3 years); 2) smoking status
(current and former); and 3) likelihood of initiating insulin therapy after
enrollment (the likelihood of initiating insulin therapy in the nonusers was
within the likelihood in the users  0.05). In the new-user cohort, follow-up in
insulin users commenced at the time of initiation of insulin therapy, for
example, 2 years after enrollment in the registry (24). To ensure comparability
of these variables in the user and nonusers in each matched pair, the follow-up
in the matched insulin nonusers also started at the same time after the
enrollment as that of the case subject, that is, 2 years using the above example.
To ensure that the matched nonusers had adequate follow-up period for
comparison with the case subject, the time period of the nonusers from
enrollment to the earliest date of cancer, death, or censoring times must be
longer than the period of the matched user from enrollment to the date of
initiating insulin therapy. For example, an insulin user started insulin 2 years
after enrollment and then developed cancer 5 years after starting insulin
therapy. A matched nonuser of the user developed cancer 6 years after
enrollment. Thus, the user had 5 years of follow-up, whereas the nonuser had
4 years of follow-up in the new-user cohort. Any nonusers who died,
developed cancer, or were censored within 2 years of enrollment were not
eligible to be a matched nonuser of the user.
The likelihood of initiating insulin therapy was calculated using a logistic
7387 enrolled since Dec 1, 1996
4623 used in organizing
the matched  new  user cohort 
Exclusion of 328 type 1 diabetes
or missing diabetes type 
Exclusion of 45 with non-Chinese
or unknown ethnicity 
Exclusion of 175 with cancer
at enrollment  
Exclusion of 736 with missing
values in variables used  
Exclusion of 1480 with ever use
of insulin at enrollment  
3650 insulin non-users  973 insulin users 
971 insulin users
with matched non-user/s
1935 insulin non-users
selected as matched non-users
FIG. 1. Patient ﬂow chart. Adjusted for use of insulin during follow-up period, and covariates as listed in the adjustment scheme of model 3 in
Table 3 plus matching criteria (i.e., age, smoking status, and probability of using insulin during follow-up period).
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the dependent variable. A forward stepwise algorithm (P  0.30 for inclusion
and removal) was used to select a group of predictors among age, sex, BMI,
LDL cholesterol, HDL cholesterol, triglyceride, smoking status, alcohol intake,
HbA1c (A1C), systolic blood pressure, Ln (spot urinary albumin-to-creatinine
ratio [ACR]1), estimated glomerular ﬁltration rate (eGFR), duration of
diabetes, peripheral arterial disease, retinopathy, sensory neuropathy, prior
myocardial infarction, and prior stroke at enrollment. Age, smoking status,
duration of diabetes, A1C, HDL cholesterol, Ln (ACR1), and retinopathy
were selected for the predicting model (C statistic  0.79 and P for Hosmer
and Lemeshow test  0.8288). The follow-up time in the new-user cohort was
calculated as the period in years from the date of initiation of insulin therapy
to the earliest date of cancer, death, or censoring. The follow-up time of the
nonusers was calculated as the difference between the follow-up time of the
nonuser in the original cohort design and the time period from enrollment to
the date of starting insulin of the corresponding user.
The 1:2-matched insulin new-user cohort has the following features: 1)
without prevalent users; 2) follow-up started at the time of initiation of insulin
therapy; 3) “baseline” characteristics in new users and matched nonusers in a
matched pair were comparable (i.e., measured at the same time away from the
starting time point of follow-up); and 4) a new user and its matched nonusers
in each matched pair had similar age, smoking status, and likelihood to initiate
insulin therapy.
Clinical and laboratory measurements. Details of assessment methods and
deﬁnitions of end points have been described elsewhere (15). In essence, on
the visit day, patients attended the center after8ho ffasting to undergo
clinical assessments and laboratory investigations. Apart from documentation
of demographic data and clinical assessment of complications, fasting blood
samples were taken for measurement of plasma glucose, A1C, lipid proﬁle
(total cholesterol, HDL cholesterol and triglyceride, calculated LDL choles-
terol), and renal function. A sterile, random spot urine sample was used to
measure ACR. Albuminuria was deﬁned as ACR 2.5 mg/mmol in men and
3.5 mg/mmol in women. The abbreviated Modiﬁcation of Diet in Renal
Disease Study formula recalibrated for Chinese (25) was used to estimate
eGFR expressed in ml  min
1  1.73 m
2: eGFR  186  (SCR  0.011)
1.154
 (age)
0.203  (0.742 if female)  1.233, where SCR is serum creatinine
expressed as mol/l (original mg/dl converted to mol/l) and 1.233 is the
adjusting coefﬁcient for Chinese. Lipids (total cholesterol, triglyceride, and
HDL cholesterol) were measured by enzymatic methods on a Hitachi 911
automated analyzer (Boehringer Mannheim, Mannheim, Germany) using
reagent kits supplied by the manufacturer of the analyzer. LDL cholesterol
was calculated using Friedewald equation (26). The precision performance of
these assays was within the manufacturer’s speciﬁcations.
Deﬁnition of cancer. A trained team of personnel of the Hospital Authority
routinely coded all the hospital discharge principal diagnoses including cancer
and noncancer hospital admissions according to the International Classiﬁca-
tion of Diseases, Ninth Revision (ICD-9). Hospital discharge principal diag-
noses, coded by ICD-9, were used to identify cancer events. The end point of
this study was deﬁned as having ﬁrst incident cancer during follow-up
(regardless of whether it was fatal or nonfatal; codes 140–208).
Statistical analyses. The SAS (Release 9.10) was used to perform the
statistical analysis (SAS Institute, Cary, NC). The propensity score was
calculated in the original cohort and automatically exported to a new SAS
dataset. Then, matching was performed using SAS programming. After the
matched new-user cohort dataset was generated, we performed stratiﬁed Cox
proportional hazard regression analysis on the matched pairs to obtain hazard
ratios (HRs) of initiation of insulin therapy and A1C for incident cancer.
A structured adjustment scheme was used to adjust for covariates. First,
we obtained HR of use of insulin and A1C without adjusting for other
covariates. Because we have previously reported the nonlinear risk associa-
tions of cancer with LDL cholesterol at values 2.8 mmol/l and 3.8 mmol/l,
which were further modiﬁed by other parameters (27), we secondly adjusted
for covariates with P  0.30 selected by the stepwise algorithm among these
cancer-associated LDL cholesterol–related risk interaction terms (indicator
terms for LDL cholesterol 2.8 mmol/l plus albuminuria and 3.8 mmol/l)
(27): sex, duration of diabetes, alcohol intake (current and former), HDL
cholesterol, triglyceride, systolic blood pressure, eGFR, Ln (ACR1), use of
antihypertensive drugs at enrollment, and use of ACE inhibitors or angioten-
sin II receptor blockers, statins, ﬁbrates, and oral antidiabetic drugs (Table 1)
from enrollment to cancer, death, or censoring dates, whichever came ﬁrst.
Third, restricted cubic spline was used in the stratiﬁed Cox model to adjust for
nonlinear associations of covariates with cancer as previously reported (16).
The curve of HR versus A1C was calculated using restricted cubic spline (28)
as previously reported (15,29). In addition, a life table method (Statistical
Package for the Social Sciences for Windows, Release 13.0; SPSS, Chicago, IL)
was used to examine the differences in the cumulative incidences of cancer
and death over time.
Correlations between pairs of baseline covariates were checked using the
Pearson correlation test and none of the pairs was highly correlated (corre-
lation coefﬁcient 0.60). Proportional hazards were checked. A two-sided P 
0.05 was considered signiﬁcant.
RESULTS
Characteristics of the original cohort. At enrollment,
the median age of the cohort (n  4,623) was 57 (25th-75th
percentiles: 47–67) years with a median duration of dia-
betes of 5 (1–10) years. The median period from enroll-
ment to the earliest date of cancer, death, or censoring
was 5.11 (2.86–7.15) years. Cancer incidence was lower in
insulin users than nonusers (5.8 per 1,000 person-years vs.
9.7 per 1,000, P  0.0082) but death incidence was higher
in insulin users than nonusers (24.0 vs. 9.6, P  0.0001).
The comparison of other variables, including drug use, is
available in Table 1.
Characteristics of the new insulin user cohort. Of 973
patients who were started on insulin therapy, 971 had at
least one matched nonuser (964 had two matched nonus-
ers and seven had only one matched nonuser). Despite this
careful matching, there were still signiﬁcant differences in
age, smoking status, and clinical and biochemical charac-
teristics between insulin nonusers and users, albeit
smaller than those in the original cohort. Compared with
noninsulin users, insulin users had longer duration of
diabetes, higher A1C, and worse lipid proﬁle (higher LDL
cholesterol, higher triglyceride, and lower HDL choles-
terol), and were more likely to have albuminuria and renal
dysfunction. Insulin users were also more likely to be
treated with ACE inhibitors/angiotensin II receptor block-
ers, statins, and oral antidiabetic drugs (in particular,
metformin) than insulin nonusers. The cancer incidence in
insulin nonusers was much higher than in insulin users
(49.2 per 1,000 person-years vs. 10.2, P  0.0001). On the
other hand, death incidence was comparable between
insulin nonusers and users (P  0.8307; Table 1).
Use of insulin and A1C for the risk of cancer. In the
new-user cohort, A1C was marginally associated with an
increased risk of cancer after adjusting for use of insulin,
age, smoking status, and likelihood of use of insulin (P 
0.0747). After further adjusting for all other covariates
with a P  0.3 (HDL cholesterol, triglyceride, eGFR, and
use of metformin), A1C per percentage was associated
with a 1.24-fold increase in the risk of cancer (95% CI
1.03–1.49, P  0.0267). The HR increased to 1.26 (95% CI
1.03–1.55, P  0.0230) after adjusting for nonlinear asso-
ciations of covariates.
Use of insulin was consistently associated with de-
creased risks of cancer after adjusting for A1C, age,
smoking status, and likelihood of use of insulin. After
further adjusting for HDL cholesterol, triglyceride, eGFR,
and use of metformin as well as taking nonlinear associa-
tions of covariates with cancer into consideration, the
multivariable HR was 0.17 (95% CI 0.09–0.32, P  0.0001).
On the other hand, use of insulin was not associated with
death in the three adjusting models (Table 2). The cumu-
lative incidence of cancer was markedly lower in insulin
users than in nonusers, although the cumulative incidence
of death was similar in insulin users and nonusers during
7 years of follow-up (Table 3).
For subsite-speciﬁc cancers, A1C was marginally asso-
ciated with a higher risk whereas use of insulin was
associated with lower risks of cancers of the digestive
system (HR 0.19, 0.08–0.46) and cancers of the nondiges-
tive systems (HR 0.20, 95% CI 0.10–0.41) (Table 4).
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4,623) to perform the sensitivity analysis, in which age,
smoking status, and likelihood of using insulin during
follow-up were used as covariates. The HR of A1C for
cancer was 1.11 (95% CI 0.98–1.26, P  0.0974) and that of
use of insulin for cancer was 0.47 (95% CI 0.31–0.71, P 
0.0003) in the model including only A1C and use of insulin
without other covariates. After adjusting for the covariates
of model 2 in Table 2, the HRs of A1C and use of insulin
were 1.17 (1.04–1.33, P  0.0125) and 0.49 (0.32–0.73, P 
0.0006), respectively. After further adjusting for nonlin-
ear associations (model 3 in Table 2), the respective
TABLE 1
Clinical and biochemical characteristics of the study patients in cohort design and new-user cohort design
Variables at enrollment
Cohort design New-user cohort design*
Insulin nonusers Insulin users P Insulin nonusers Insulin users P
n 3,650 973 1,935 971
Age (years) 56 (20) 58 (20) 0.0022† 58 (21) 58 (20)
Smoking status 0.0005‡
Former 482 (13.2%) 176 (18.1%) 348 (18.0%) 175 (18.0%)
Current 567 (15.5%) 150 (15.4%) 297 (15.4%) 149 (15.4%)
Male sex 1,678 (46.0%) 453 (46.6%) 0.7452‡ 964 (49.8%) 451 (46.5%) 0.0863‡
Alcohol use 0.0021‡ 0.1164‡
Former 385 (10.6%) 140 (14.4%) 257 (13.3%) 139 (14.3%)
Current 304 (8.3%) 68 (7.0%) 178 (9.2%) 68 (7.0%)
BMI (kg/m
2) 24.8 (4.8) 24.5 (5.1) 0.0070† 24.9 (4.9) 24.5 (5.1) 0.0014†
Duration of diabetes (years) 4 (8) 8 (8) 0.0001† 4 (9) 8 (8) 0.0001†
Systolic blood pressure (mmHg) 133 (25) 136 (29) 0.0004† 135 (26) 136 (29) 0.1787†
Diastolic blood pressure (mmHg) 75 (13) 76 (15) 0.1025† 75 (14) 76 (15) 0.0413†
A1C (%) 6.9 (1.7) 8.1 (2.5) 0.0001† 7.1 (2.0) 8.1 (2.5) 0.0001†
LDL cholesterol (mmol/l) 3.10 (1.21) 3.20 (1.2) 0.0004† 3.00 (1.26) 3.20 (1.2) 0.0001†
HDL cholesterol (mmol/l) 1.27 (0.43) 1.21 (0.46) 0.0001† 1.26 (0.43) 1.21 (0.46) 0.0002†
Triglyceride (mmol/l) 1.32 (0.96) 1.45 (1.14) 0.0004† 1.40 (0.99) 1.45 (1.14) 0.3057†
Total cholesterol (mmol/l) 5.10 (1.30) 5.20 (1.30) 0.0011† 5.05 (1.40) 5.20 (1.30) 0.0001†
ACR (mg/mmol) 1.39 (4.44) 5.00 (26.27) 0.0001† 1.93 (8.76) 4.96 (26.79) 0.0001†
Microalbuminuria 23.6% (863) 32.2% (313) 0.0001‡ 26.5% (513) 32.0% (311) 0.0001‡
Macroalbuminuria 9.8% (356) 26.3% (256) 15.3% (296) 26.4% (256)
eGFR (ml/min
1 per 1.73 m
2) 106.2 (36.6) 100.9 (50.3) 0.0001† 101.2 (38.1) 100.9 (50.3) 0.1342†
60 4.7% (173) 14.9% (145) 0.0001‡ 7.3% (142) 14.9% (145) 0.0001‡
Retinopathy 612 (16.8%) 355 (36.5%) 0.0001‡ 454 (23.5%) 354 (36.5%) 0.0001‡
Prior myocardial infarction 55 (1.5%) 13 (1.3%) 0.6942‡ 42 (2.2%) 13 (1.3%) 0.1207‡
Prior stroke 144 (4.0%) 43 (4.4%) 0.5048‡ 96 (5.0%) 43 (4.4%) 0.5255‡
Medications at enrollment
Antihypertensive drugs other
than ACEIs/ARBs 1,351 (37.0%) 377 (38.8%) 0.3210‡ 828 (42.8%) 375 (38.6%) 0.0313‡
Events and medications after
enrollment§
Cancer during follow-up 169 (4.6%) 32 (3.3%) 0.0683‡ 120 (6.3%) 32 (3.3%) 0.0009‡
Follow-up time to cancer,
years 4.78 (4.43) 6.04 (3.55) 0.0001‡ 0.70 (1.23) 3.01 (3.51) 0.0001‡
Incidence of cancer, per 1,000
person-years
9.7
(8.3–11.1)§
5.8
(3.8–7.8)§ 0.0082
49.2
(40.6–57.8)§
10.2
(6.7–13.7)§ 0.0001
Death during follow-up 169 (4.6%) 133 (13.7%) 0.0001‡ 125 (6.5%) 132 (13.6%) 0.0001‡
Follow-up time to death, years 4.78 (4.43) 6.04 (3.55) 0.0001‡ 0.77 (1.57) 3.09 (3.45) 0.0001‡
Incidence of death, per 1,000
person-years
9.6
(8.1–11.0)§
24.0
(19.9–28.0)§ 0.0001
46.5
(38.5–54.4)§
41.2
(34.3–48.1)§ 0.8307
ACEIs or ARBs 1,750 (48.0%) 705 (72.5%) 0.0001‡ 1,009 (52.1%) 703 (72.4%) 0.0001‡
Statins 1,088 (29.8%) 506 (52.1%) 0.0001‡ 605 (31.2%) 506 (52.1%) 0.0001‡
Fibrates 327 (9.0%) 121 (12.4%) 0.0011‡ 163 (8.4%) 120 (12.4%) 0.0007‡
Acarbose 287 (7.9%) 269 (27.7%) 0.0001‡ 177 (9.2%) 269 (27.7%) 0.0001‡
Glibenclimide 1,046 (28.7%) 396 (40.7%) 0.0001‡ 482 (24.9%) 395 (40.7%) 0.0001‡
Gliclazide 1,692 (46.4%) 603 (62.0%) 0.0001‡ 956 (50.1%) 602 (62.0%) 0.0001‡
Glimepiride 38 (1.0%) 33 (3.4%) 0.0001‡ 24 (1.2%) 33 (3.4%) 0.0001‡
Glipizide 399 (10.4%) 197 (20.3%) 0.0001‡ 221 (11.4%) 197 (20.3%) 0.0001‡
Metformin 2,680 (73.4%) 837 (86.0%) 0.0001‡ 1,442 (74.5%) 835 (86.0%) 0.0001‡
Pioglitazone 25 (0.7%) 17 (1.8%) 0.0019‡ 18 (0.9%) 17 (1.8%) 0.0558‡
Rosiglitazone 106 (2.9%) 110 (11.3%) 0.0001‡ 64 (3.3%) 110 (11.3%) 0.0001‡
Tolbutamide 10 (0.3%) 22 (2.3%) 0.0001‡ 8 (0.4%) 21 (2.2%) 0.0001‡
Data are median (interquartile range; from 25th-75th percentiles), % (n), and n (%). *Matched on age, smoking status, likelihood of using
insulin, and time before insulin use. †Derived from Wilcoxon two-sample test. ‡Derived from 
2 test. §From enrollment to the earliest date
of cancer, death, or censoring (95% CIs). Derived from univariate Cox model analysis. ACEIs, angiotensin-converting enzyme inhibitors;
ARBs, angiotensin II receptor blockers.
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insulin (0.48, 0.32–0.73, P  0.0006) remained similar.
The full range of association between A1C and cancer is
shown in Fig. 2.
DISCUSSION
In a new insulin user cohort of Chinese patients with type
2 diabetes, hyperglycemia was associated with an in-
creased cancer risk, whereas insulin use was associated
with a reduced cancer risk. However, both insulin and
noninsulin users had similar incidence of all-cause death.
A series of observational studies have examined
whether insulin glargine users were at higher risk of
cancer than users of other types of insulin or metformin
(5–8). Whereas researchers from the U.K. observed that
users of insulin or insulin secretagogues had a higher
cancer risk than metformin users (8), in the Swedish study
(6) and the Scottish study (7), there was no increased
cancer risk in patients treated with insulin glargine com-
pared with users of other types of insulin.
Because use of metformin may be associated with a
lower cancer risk (30,31), the result from the U.K. study
cannot address the association between use of insulin and
cancer. Adding to this confusion, the German study (5)
reported that insulin glargine users were at a lower overall
risk of cancer than human insulin users after adjusting for
age and sex (relative risk 0.86, 95% CI 0.79–0.94). How-
ever, after adjustment for dosage, the authors found a
“dose-dependent” increase in cancer risk with glargine
compared with human insulin (5). On the other hand, we
and others (12,13) have reported that hyperglycemia was a
risk factor for cancer in type 2 diabetes. Thus, the dose-
effect relationship for cancer in the German study (5) may
be confounded by severe hyperglycemia in the high-dose
insulin glargine groups.
Traditional cohort design versus new-user design. It
is usual to use cohort studies to address possible drug
effects, but cohort study designs may have difﬁculties in
controlling for some potential confounding factors. The
so-called prevalent user bias is considered a major con-
tributing factor that results in discrepancies between
observational studies and clinical trials. Compared with
traditional cohort study designs, a new-user design can
eliminate insufﬁcient ascertainment of events that occur
early in therapy and allow better control for disease risk
factors that may have been altered by the study drugs in
question. One of the main rationales underlying new-user
designs is to synchronize the beginning of study follow-up
TABLE 2
HRs of use of insulin for cancer in a cohort of 971 insulin new
users and 1,935 insulin nonusers matched on age, smoking status,
and the likelihood of using insulin
HR* 95% CI P
Models for cancer*
Model 1†
A1C (%) 1.16 0.99–1.36 0.0747
Use vs. nonuse of insulin 0.18 0.10–0.33 0.0001
Model 2‡
A1C (%) 1.24 1.03–1.49 0.0267
Use vs. nonuse of insulin 0.18 0.10–0.33 0.0001
Model 3§
A1C (%) 1.26 1.03–1.55 0.0230
Use vs. nonuse of insulin 0.17 0.09–0.32 0.0001
Models for death*
Model 1†
Use vs. nonuse of insulin 1.27 0.92–1.75 0.1543
Model 2
Use vs. nonuse of insulin 1.24 0.84–1.84 0.2739
Model 3¶
Use vs. nonuse of insulin 1.28 0.85–1.94 0.2422
*Stratiﬁed Cox models on the matching pairs were used. †Not adjusted
for other covariates. ‡Adjusted for HDL cholesterol, triglyceride, eGFR,
and use of metformin. Other variables had a P value larger than 0.3 and
not selected by the stepwise algorithm with P  0.30. These variables
included sex, alcohol drinking (previous and current), duration of
diabetes, BMI, systolic blood pressure, LDL cholesterol–related risk
(indicator terms for LDL cholesterol 2.8 mmol/l plus albuminuria and
3.8 mmol/l), Ln (ACR1), use of antihypertensive drugs (other than
ACEIs or ARBs) at enrollment, and use of drugs from enrollment to the
earliest date of cancer, death, or censoring (ACEIs or ARBs, statins,
ﬁbrates, and oral antidiabetic drugs listed in Table 1). §Restricted cubic
spline was further used to adjust for nonlinear associations between
HDL cholesterol and triglyceride with cancer. Adjusted for A1C, BMI,
eGFR, Ln(ACR1), use of antihypertensive drugs (other than ACEIs or
ARBs) at enrollment, and use of ACEIs or ARBs, ﬁbrates, gliclazide, and
rosiglitazone from enrollment to the earliest date of cancer, death, or
censoring (selected by the stepwise algorithm with P  0.30). ¶Re-
stricted cubic spline was further used to adjust for nonlinear associa-
tions among A1C, BMI, ACR, and eGFR with death.
TABLE 3
Life table analyses of development of cancer and total death in new insulin users and a matched cohort of insulin nonusers
At risk at the beginning
of the period Cancer cases Deaths in the period
Cumulative cancer
rate (%)†
Cumulative death
rate (%)‡
Insulin users
Year 1* 971 12 50 1.3 5.4
Year 2* 807 6 20 2.2 8.0
Year 3* 628 4 20 2.9 11.2
Year 4* 487 7 18 4.5 14.9
Year 5* 334 1 14 4.8 18.9
Year 6* 226 1 6 5.4 21.5
Year 7* 126 0 1 5.4 22.3
Insulin nonusers
Year 1* 1,935 90 73 6.5 5.2
Year 2* 751 21 25 9.9 8.9
Year 3* 389 3 15 10.8 12.7
Year 4* 220 4 6 12.8 15.1
Year 5* 133 1 5 13.6 18.3
Year 6* 73 1 0 15.2 18.3
Year 7* 36 0 0 15.2 18.3
*From the ﬁrst day of follow-up through the end of the year. †P from Wilcoxon (Gehan) statistic 0.0001 for comparison between insulin
users and nonusers. ‡P from Wilcoxon (Gehan) statistic  0.7408 for comparison between insulin users and nonusers.
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this principle may introduce major bias, such as confound-
ing by risk factors that are associated with both therapy
indication and clinical outcomes, with conclusions that
are scientiﬁcally disastrous (32). This is clearly illustrated
by the recent controversy on insulin use and cancer; in a
non–new-user cohort design, patients with uncontrolled
hyperglycemia may be at high risk of cancer but are also
more likely to be given insulin. The latter was then
erroneously identiﬁed as a risk factor for cancer.
On the other hand, by controlling for all confounders,
including risk factors, complications, use of medications,
and duration of follow-up with respect to start of insulin in
a new-cohort design, we were able to show the indepen-
dent cancer risk with A1C and that of reduction of cancer
with insulin therapy. Our sensitivity analysis using the
traditional cohort design without including prevalent users
also shows similar results. However, in the latter analysis,
because nonuse of insulin from enrollment to initiation of
insulin treatment was treated as “on-insulin” period, this
can attenuate the true association of insulin with cancer
compared with the new-user cohort.
Adjustment for other confounders and competing
risks. With improved survival from cardiorenal complica-
tions, cancer has become an important health hazard in
diabetic patients. In this regard, competing risk (i.e.,
noncancer death) is unlikely to be a potential source of
bias in our analysis because proportional hazard models
such as Cox models can still give valid results when used
to test HR (33). In addition, in this new-user cohort design,
the cumulative death rates were similar in insulin users
and nonusers during 7 years of follow-up, and the adjusted
HRs of use of insulin for death were nonsigniﬁcant,
suggesting that the impacts of competing risk on our
results, if any, are very small.
Hyperglycemia, dyslipidemia, inﬂammation, dysregu-
lated cellular growth, insulin resistance, and hyperinsulin-
emia can all contribute to cardiorenal complications and
cancer in diabetic patients. Recently, we reported poten-
tial cross talk between lipid metabolism and the RAS in
development of cancer in type 2 diabetes, possibly via the
IGF-I signaling and cholesterol biosynthesis pathways
(19). Of note, hyperglycemia has a potent but reversible
effect on LDL oxidation (20). Oxidized LDL (ox-LDL)
enhances the expression and activation of RAS compo-
nents; the latter can in turn stimulate the accumulation of
LDL and its oxidation into ox-LDL, thus setting up a
vicious cycle (18). Individually, ox-LDL and RAS activation
induce oxidative stress and inﬂammatory cascade (18).
Thus, it is plausible that insulin use may reduce oxidative
stress and inﬂammation by lowering blood glucose and
thus reduce cancer risk. Indeed, in patients in whom
hyperglycemia is the predominant metabolic risk factor
for cancer, the theoretic growth-promoting and mitogenic
effects of insulin on cancer development may be less
important.
Despite its biological plausibility, other methods are
needed to conﬁrm these arguments, such as mechanistic
and intervention studies. Unlike a clinical trial, measure-
ment of A1C during these follow-up visits in real practice
was not standardized, and thus the availability and
changes in A1C levels may be biased in this epidemiologic
analysis. If insulin could increase cancer risk by modulat-
ing cell growth, circulating insulin levels would presum-
ably be important. Patients who required insulin may have
lower natural levels than those who did not; therefore,
supplementary insulin in these patients may increase the
circulating insulin level comparable only with a natural
level, which is not likely to increase cancer risk. Never-
theless, hyperinsulinemia remains an important issue in
cancer risk and further studies are required to determine
this risk association.
TABLE 4
HRs of use of insulin vs. nonuse for ﬁrst incident cancers in a cohort of 971 insulin new users and 1,935 insulin nonusers matched
on age, smoking status, and likelihood of using insulin
Cancer subtypes* No. of cancers* HR (95% CI) of A1C† HR (95% CI) of insulin†
Lip, oral cavity, and pharynx 3
Digestive organs and peritoneum 65 1.19 (0.95–1.51) 0.19 (0.08–0.46)
Upper digestive tract 10
Lower digestive tract 25
Liver and intrahepatic bile ducts 19
Respiratory and intrathoracic organs 19
Bone, connective tissue, skin, and breast 19
Genitourinary organs 24
Lymphatic and hematopoietic tissue 7
Other and unspeciﬁed sites 15
Cancers other than digestive organs and peritoneum cancer 87 1.13 (0.91–1.41) 0.20 (0.10–0.41)
*A total of 152 cancers of any type classiﬁed by the ICD-9 were analyzed. †Derived from stratiﬁed Cox models without adjusting for other
covariates, but A1C and use of insulin were simultaneously entered in each of these models.
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FIG. 2. Hazard ratio of A1C for incident cancer in the cohort of 4,623
Chinese patients with type 2 diabetes.
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interpreted with caution because of study limitations.
First, the follow-up time was relatively short, but the
observed association of use of insulin on cancer was larger
than expected. Second, because of the observational na-
ture of the study, A1C was not systematically collected
during follow-up visits. Third, principal discharge diag-
noses were used to identify cancer cases. However, only a
small number of cancer events would be missed, mainly
due to patient emigration or treatment in the private
sector. Fourth, the cohort was mainly clinic based, albeit
the overall clinical proﬁle was comparable with many
community-based cohorts (22). Fifth, although we used a
new-user study design (24), both measured and unmea-
sured confounders may still exist.
In conclusion, in a matched cohort of Chinese type 2
diabetic patients newly started on insulin, hyperglycemia
was associated with an increased cancer risk, whereas
insulin use was associated with a reduced cancer risk.
Apart from reafﬁrming the importance of controlling hy-
perglycemia to prevent poor clinical outcomes, including
cancer, at least in Chinese patients with type 2 diabetes,
our use of a new-cohort design coupled with careful
adjustment for confounding variables has provided a new
strategy in pharmacoepidemiologic analysis.
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